|
|
|
Unmet medical needs in IT pain management1-6
Patients may become refractory to IT therapy due to
Do you recognize this pattern?1-5
PRIALT is indicated for the management of severe chronic pain in patients for whom
intrathecal (IT) therapy is warranted, and who are intolerant of or refractory to
other treatment, such as systemic analgesics, adjunctive therapies or IT morphine.
Please see accompanying
full prescribing information including boxed WARNING and important safety information.
References:
- Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects.
Pain Physician. 2008;11:S105-S120.
- Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med. 2003;349(20):1943-1953.
- Ballantyne JC. Opioids for chronic nonterminal pain. South Med J. 2006;99(11):1245-1255.
- Hassenbusch SJ, Garber J, Buchser E, Du Pen S, Nitescu P. Alternative intrathecal
agents for the treatment of pain. Neuromodulation. 1999;2(2):85-91.
- Duramorph (morphine sulfate injection, USP) Prescribing Information. Baxter Healthcare
Corporation. Deerfield, IL.
- Coffey RJ, Burchiel K. Inflammatory mass lesions associated with intrathecal drug
infusion catheters: report and observation on 41 patients. Neurosurgery.
2002;50(1):78-87.
|
|
|
